Active Ingredient History

  • Now
Orphenadrine is an anticholinergic drug of the ethanolamine antihistamine class used to treat muscle pain and to help with motor control in Parkinson's disease but has largely been superseded by newer drugs. Orphenadrine binds and inhibits both histamine H1 receptors and NMDA receptors. It restores the motor disturbances induced by neuroleptics, in particular, the hyperkinesia. The dopamine deficiency in the striatum increases the stimulating effects of the cholinergic system. This stimulation is counteracted by the anticholinergic effect of orphenadrine. It may have a relaxing effect on skeletal muscle spasms and it has a mood elevating effect. Orphenadrine is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. Orphenadrine is an anticholinergic with a predominantly central effect and only a weak peripheral effect. In addition, it has mild antihistaminic and local anesthetic properties. Parkinson's syndrome is the consequence of a disturbed balance between cholinergic and dopaminergic neurotransmission in the basal ganglia caused by a decrease in dopamine. Orphenadrine restores the physiological equilibrium and has a favorable effect on the rigidity and tremor of Parkinson's disease and Parkinsonian syndromes. Adverse reactions of orphenadrine citrate are mainly due to the mild anticholinergic action of orphenadrine citrate and are usually associated with higher dosage. Dryness of the mouth is usually the first adverse effect to appear. When the daily dose is increased, possible adverse effects include tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilatation of pupils, increased ocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, hypersensitivity reactions, pruritus, hallucinations, agitation, tremor, gastric irritation and rarely urticaria and other dermatoses   NCATS

More Chemistry

Drug Pricing (per unit)

United States

$0.1969 - $7.7090
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( caffeine, acetylsalicylic acid (aspirin), orphenadrine hydrochloride (disipal) - other names: invagesic, invagesic forte, norgesic forte, orphengesic, orphengesic forte )
2-methyldiphenhydramine | 2-(phenyl-o-tolylmethoxy)ethyldimethylamine | beta-dimethylaminoethyl 2-methylbenzhydryl ether | biorphen | dimethyl-[2-(phenyl-o-tolyl-methoxy)-ethyl]-amine | disipal | invagesic | n,n-dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine | n,n-dimethyl-2-[(o-methyl-alpha-phenylbenzyl)oxy]ethylamine | n,n-dimethyl-2-(phenyl(o-tolyl)methoxy)ethanamine | norflex | norgesic | o-methyldiphenhydramine | o-monomethyldiphenhydramine | orfenadrina | orphenadine | orphenadine citrate | orphenadrin | orphenadrine | orphenadrine caffeine | orphenadrine chloride | orphenadrine (chloride) | orphenadrine citrate | orphenadrine (citrate) | orphenadrine hcl | orphenadrine hydrochloride | orphenadrinum | orphengesic | phenyl-o-tolylmethyl dimethyaminoethyl ether | β-dimethylaminoethyl 2-methylbenzhydryl ether


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue